ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,996.66
      1.00%
      US Tech 100
      20,877.20
      1.72%
      Dow Jones
      43,487.83
      0.78%
      Brent Oil
      79.04
      -1.46%
      Bitcoin
      105,851.74
      2.66%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. NovoCure Ltd (NVCR) Quote

      NovoCure Ltd

      NovoCure Ltd (NVCR)

      NASDAQ
      26.17
      0.15
      (0.58%)
      Closed January 20 4:00PM
      Delayed by 15 minutes
      26.17
      0.00
      (0.00%)
      After Hours: 6:14PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      26.17
      Bid
      18.00
      Ask
      33.88
      Volume
      1,184,326
      25.66 Day's Range 27.105
      11.70 52 Week Range 34.13
      Market Cap
      2.832B
      Previous Close
      26.02
      Open
      25.66
      Last Trade
      9
      @
      26.53
      Last Trade Time
      Financial Volume
      $ 30,881,729
      VWAP
      26.0754
      Average Volume (3m)
      1,270,213
      Shares Outstanding
      108,201,434
      Dividend Yield
      -
      PE Ratio
      -13.68
      Earnings Per Share (EPS)
      -1.91
      Revenue
      509.34M
      Net Profit
      -207.04M

      About NovoCure Ltd

      NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives it... NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States. Show more

      Sector
      Surgical,med Instr,apparatus
      Industry
      Surgical,med Instr,apparatus
      Website
      www.novocure.com
      Headquarters
      Jersey, Gbr
      Founded
      -
      NovoCure Ltd is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker NVCR. The last closing price for NovoCure was $26.02. Over the last year, NovoCure shares have traded in a share price range of $ 11.70 to $ 34.13.

      NovoCure currently has 108,201,434 shares outstanding. The market capitalization of NovoCure is $2.82 billion. NovoCure has a price to earnings ratio (PE ratio) of -13.68.

      Ask ADVFN Intelligence (AI)

      NVCR Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      January 15 2025
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      January 13 2025
      Edgar (US Regulatory)

      Form 8-K - Current report

      January 13 2025
      Edgar (US Regulatory)

      Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

      Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST...

      January 13 2025
      Business Wire

      Form 3 - Initial statement of beneficial ownership of securities

      January 06 2025
      Edgar (US Regulatory)

      Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

      Novocure (NASDAQ: NVCR) announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive...

      January 03 2025
      Business Wire

      Novocure annonce des résultats positifs de l'essai clinique de phase 3 PANOVA-3 sur les champs de traitement des tumeurs (TTFields) pour le cancer du pancréas

      PANOVA-3 a atteint son objectif principal avec une amélioration statistiquement importante de la survie globale des patients atteints d'un adénocarcinome pancréatique non résécable et localement...

      December 05 2024
      Business Wire

      ノボキュア、膵がんに対する腫瘍治療電場療法（TTフィールド）の第3相臨床試験PANOVA-3のトップライン結果を発表

      PANOVA-3試験でゲムシタビンおよびnab-パクリタキセルと併用したTTフィールドを一次治療として用いた切除不能な局所進行膵腺がん患者の全生存期間が統計的に有意に改善、主要評価項目を達成 アメリカ、EU、日本...

      December 04 2024
      Business Wire

      Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

      PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the...

      December 02 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.87-6.6690442225428.0428.5625.46117582226.84134939CS
      4-4.16-13.715792944330.3332.05525.4696297428.95017573CS
      129.6158.031400966216.5634.1315.1127021325.76247332CS
      267.439.424613745318.7734.1314.17118158021.73185903CS
      5213.82111.90283400812.3534.1311.7125031619.01354628CS
      156-41.83-61.514705882468120.0310.87108361337.91640063CS
      260-68.83-72.452631578995232.7610.8799749066.73503406CS

      NVCR - Frequently Asked Questions (FAQ)

      What is the current NovoCure share price?
      The current share price of NovoCure is $ 26.17
      How many NovoCure shares are in issue?
      NovoCure has 108,201,434 shares in issue
      What is the market cap of NovoCure?
      The market capitalisation of NovoCure is USD 2.82B
      What is the 1 year trading range for NovoCure share price?
      NovoCure has traded in the range of $ 11.70 to $ 34.13 during the past year
      What is the PE ratio of NovoCure?
      The price to earnings ratio of NovoCure is -13.68
      What is the cash to sales ratio of NovoCure?
      The cash to sales ratio of NovoCure is 5.56
      What is the reporting currency for NovoCure?
      NovoCure reports financial results in USD
      What is the latest annual turnover for NovoCure?
      The latest annual turnover of NovoCure is USD 509.34M
      What is the latest annual profit for NovoCure?
      The latest annual profit of NovoCure is USD -207.04M
      What is the registered address of NovoCure?
      The registered address for NovoCure is NO 4 THE FORUM, GRENVILLE STREET, ST. HELIER, JERSEY, JE2 4UF
      What is the NovoCure website address?
      The website address for NovoCure is www.novocure.com
      Which industry sector does NovoCure operate in?
      NovoCure operates in the SURGICAL,MED INSTR,APPARATUS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BTCTBTC Digital Ltd
      $ 8.2697
      (73.73%)
      		61.45M
      BDMDBaird Medical Investment Holdings Ltd
      $ 8.80
      (62.36%)
      		18.63M
      CRKNCrown Electrokinetics Corporation
      $ 0.1235
      (54.96%)
      		764.86M
      NUKKNukkleus Inc
      $ 29.97
      (45.98%)
      		19.09M
      GSITGSI Technology
      $ 3.97
      (44.36%)
      		87.7M
      DOGZDogness International Corporation
      $ 18.23
      (-58.77%)
      		740.45k
      ORKTOrangeKloud Technology Inc
      $ 3.02
      (-24.88%)
      		21.08M
      PMAXPowell Max Ltd
      $ 0.6364
      (-23.31%)
      		4.17M
      LGCBLinkage Global Inc
      $ 0.2876
      (-22.27%)
      		890.66k
      YYAIConnexa Sports Technologies Inc
      $ 0.8299
      (-20.20%)
      		602.48k
      CRKNCrown Electrokinetics Corporation
      $ 0.1235
      (54.96%)
      		764.86M
      GCTKGlucoTrack Inc
      $ 0.0852
      (15.45%)
      		465.22M
      RIMEAlgorhythm Holdings Inc
      $ 0.0406
      (-4.02%)
      		387.23M
      TGLTreasure Global Inc
      $ 0.2459
      (14.75%)
      		267.1M
      NVDANVIDIA Corporation
      $ 137.71
      (3.10%)
      		201.4M

      NVCR Discussion

      View Posts
      jondoeuk jondoeuk 1 week ago
      KEYNOTE-D58 is a pivotal trial (N=741) of Optune concomitant with temozolomide plus keytruda in ndGBM. The estimated primary completion date is April 2029.
      👍️0
      jondoeuk jondoeuk 1 week ago
      Data from the PhII 2-THE-TOP trial https://www.onclive.com/view/temozolomide-pembrolizumab-plus-ttfields-leads-to-tumor-control-in-newly-diagnosed-glioblastoma
      👍️0
      KIPK KIPK 2 weeks ago
      dennisbabe - You are not smart enough to be impactful one way or another..
      You are just one irrelevant poster.....
      👍️0
      KIPK KIPK 2 weeks ago
      LOL - Garbage post....
      👍️0
      PonkenPlonken PonkenPlonken 2 weeks ago
      thank you very much for sharing jondoeuk!
      👍️0
      jondoeuk jondoeuk 2 weeks ago
      It is a pilot trial, but mPDAC is the largest category at diagnosis. Depending on the data (and if a pivotal trial ends up being successful), TTFs could eventually be used across all diagnosis categories.
      👍️0
      whosleftholdindabag whosleftholdindabag 3 weeks ago
      Wishing a Happy New Year to everyone who is invested in $NVCR!
      👍️0
      KIPK KIPK 3 weeks ago
      dennisdave, you & FeMike are made for each other. The two Irrelevant Scam Artistwannabies, begging for attention..

      You are both piles of SSSSSSSSSSSSS.......HIT....
      👍️0
      KIPK KIPK 4 weeks ago
      And you jondickuk, crawling around to save your clients from bad advise you capable of giving..

      LOL....
      👍️0
      whosleftholdindabag whosleftholdindabag 1 month ago
      $NVCR has reached its 52-week high! Wishing everyone a great weekend! GLTA
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      Thank you for sharing!
      They seem to believe this makes it to market in CRC is my read.
      👍️0
      jondoeuk jondoeuk 2 months ago
      A phase 2 trial, PANOVA-4, will test TTFields combined with a triplet regimen of gemcitabine, nab-paclitaxel and atezolizumab as a first-line treatment for metastatic pancreatic ductal adenocarcinoma. It has completed enrolment and the company said it expects to have data in 2026.

      The primary endpoint is disease control rate (DCR). Secondary endpoints include, overall survival (OS), progression-free survival (PFS), 1-year OS rate, objective response rate (ORR), PFS at 6 months, duration of response, and safety.
      👍️0
      whosleftholdindabag whosleftholdindabag 2 months ago
      $NVCR what a great way to kick off December, don't you know? Where are all the bloody naysayers today? We're raising a lot of money for charity! GLTA
      👍️0
      jondoeuk jondoeuk 2 months ago
      Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets; Zai Lab plans to file for regulatory approval in China https://www.businesswire.com/news/home/20241202363277/en/Zai-Lab-and-Novocure-Announce-Positive-Topline-Results-from-Phase-3-PANOVA-3-Clinical-Trial-of-Tumor-Treating-Fields-TTFields-Therapy-for-Pancreatic-Cancer
      👍️ 1
      tw0122 tw0122 2 months ago
      Looking good $30 +
      50% 
      12:09 PM EST, 12/02/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)NovoCure's (NVCR) shares rose more than 41% in recent Monday trading after the company and Zai Lab (ZLAB) said that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.NovoCure (NVCR) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab plans to file for regulatory approval in China, the companies said.
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      would love to see new session high
      data is hot --- Can become SOC
      👍️0
      whosleftholdindabag whosleftholdindabag 2 months ago
      $NVCR back above $20! GLTA
      👍️0
      Invest-in-America Invest-in-America 3 months ago
      NVCR: One has to be patently BRAIN DEAD to attribute any significance whatsoever to the 1890's-like ELECTRICAL, cure-all, gadgets that this obvious SCAM company promotes!!!
      👍️ 1
      jondoeuk jondoeuk 3 months ago
      FDA Approves Novocure’s Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer https://www.businesswire.com/news/home/20241015381082/en
      👍️ 1 💥 1
      whosleftholdindabag whosleftholdindabag 3 months ago
      Lovely action AH $NVCR! I can't wait for the opening bell, wishing everyone a great evening! GLTA
      👍️0
      whosleftholdindabag whosleftholdindabag 3 months ago
      $NVCR great way to end the trading day! GLTA
      👍️0
      whosleftholdindabag whosleftholdindabag 3 months ago
      I own both $NVCR and $NWBO, all proceeds will go to charity. GLTA
      👍️0
      KIPK KIPK 3 months ago
      Glad to see you are in the right stock, NWBO, now!!
      👍️0
      TiltMyBrain TiltMyBrain 5 months ago
      Who is the bag holder now???

      Going to single digits
      👍️ 1
      whosleftholdindabag whosleftholdindabag 6 months ago
      Come fly with me, let's fly let's fly away! Ol blue eyes, what a beautiful voice! Great start $NVCR! GLTA
      🚽 1
      whosleftholdindabag whosleftholdindabag 6 months ago
      Back above $20 $NVCR! GLTA
      👍️0
      whosleftholdindabag whosleftholdindabag 8 months ago
      Another week, another beautiful day for $NVCR shareholders! GLTA
      🐀 1
      whosleftholdindabag whosleftholdindabag 8 months ago
      Another beautiful start of the week for $NVCR! GLTA
      👍️0
      KIPK KIPK 8 months ago
      LOL - Go from over $200 to $20.
      Wondering why this charity worker is NWBO hater.
      Wondering why a self proclaimed good spirit tries so hard to destroy a great cancer therapy company. NWBO, hat is not NVCR??
      A true charity worker expected to be compassionate, caring, and greatful of all possible potentials...

      BUT not this guy??

      You judge!!!

      KARMA!!
      👍️ 3 💯 2
      whosleftholdindabag whosleftholdindabag 8 months ago
      GO $NVCR GO! We're making A LOT of $$$$$ for charities don't you know? GLTA
      ⚠️ 1
      whosleftholdindabag whosleftholdindabag 8 months ago
      Beautiful day $NVCR! GLTA
      👎️ 1 🤣 2
      whosleftholdindabag whosleftholdindabag 8 months ago
      It's been another great week for $NVCR! Have a wonderful weekend everyone! GLTA
      👎️ 1 🚫 1 🤣 1
      TiltMyBrain TiltMyBrain 8 months ago
      Insiders to sell shares in 30 days
      👍️ 2 💥 2
      KIPK KIPK 9 months ago
      LOL 🤣🤣🤣
      👍️ 1 💯 1
      dstock07734 dstock07734 9 months ago
      Or you can simply wait.
      👍️ 1 🤣 2
      whosleftholdindabag whosleftholdindabag 9 months ago
      Well that's fantastic mate! Perhaps I'll have my lawyer contact her, have a great weekend! GLTA
      🤣 1 ⚠️ 1
      dstock07734 dstock07734 9 months ago
      By now, you should be smart enough to know that Laura Posner or Elliott Leary would be able to get IP address of each poster on NWBO board.
      👍️ 3
      dstock07734 dstock07734 9 months ago
      libel? Which part is libel? Nemesis18's post style is very similar to yours, would you agree?
      👍️ 3 🤣 2
      whosleftholdindabag whosleftholdindabag 9 months ago
      No, do you? GLTA
      ⚠️ 1
      whosleftholdindabag whosleftholdindabag 9 months ago
      I'd be careful you're getting a wee bit close to libel don't you know? GLTA
      🚫 1 🤣 1
      whosleftholdindabag whosleftholdindabag 9 months ago
      Great way to end the week! Finish strong $NVCR! Have a great weekend everyone! GLTA
      🚫 1 🤣 1
      whosleftholdindabag whosleftholdindabag 9 months ago
      You're posting on the wrong board mate, $NWBO is the one dealing with toxic financers go over there and post your rubbish! GLTA

      Streeterville Capital, LLC is a Chicago-based company owned by John M. Fife, who has been described as a "toxic lender" for many years. Toxic financing is a type of financing that companies use when they are in poor condition and can't get financing in any other way. It can come in the form of convertible debt or convertible preferred stock and often gives the debtholder an unlimited number of common shares when they convert their debt or preferred shares to common stock.
      👍️ 1
      TiltMyBrain TiltMyBrain 9 months ago
      Toxic financing for a company who’s price is down 90% in last 3 years
      👍️ 2 💥 2
      TiltMyBrain TiltMyBrain 9 months ago
      Today is the pump. Tomorrow is the insider dump
      👍️ 2 💥 2
      KIPK KIPK 9 months ago
      What a great day right Nemeses 18?
      How is dat charity holding da bag???
      👍️ 1 😂 2 🤣 1
      KIPK KIPK 9 months ago
      Gone with the wind on wings of fake therapy IMO
      👍️ 1 💯 1
      KIPK KIPK 9 months ago
      20? including a PRE-CLINICAL???? lol
      And all that unfocused activity signal the total desperation to keep the SP up IMO...

      Reminds me of INO, which also kept throwing stuff at every possible thing, hoping one would stick.... But NO... INO SP at one time was over $2000 & now is around $11 after a recent RS
      👍️0
      axelvento axelvento 9 months ago
      Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

      https://www.biospace.com/article/releases/novocure-announces-20-presentations-on-tumor-treating-fields-highlighting-preclinical-effects-in-pancreatic-cancer-and-immune-effects-at-american-association-for-cancer-research-aacr-annual-meeting-2024/
      👎️ 2 🤣 1
      TiltMyBrain TiltMyBrain 10 months ago
      https://x.com/peter_brit/status/1775041789889491437?s=46&t=1nHn7IXseo2gJ7ymtRCgUA

      This ship is sinking fast!
      👍️ 3 👏 3
      TiltMyBrain TiltMyBrain 10 months ago
      insider selling in 3...2...1...
      👍️ 3 💯 3 😂 1 🤣 1

      Your Recent History

      NASDAQ
      NVCR
      NovoCure
      COIN
      ANMLUSD
      Animal Concerts Token
      BIT
      S27007
      Societe Generale Effekten
      BIT
      P1KR17
      BNP Paribas Issuance
      BIT
      P1H7F8
      BNP Paribas Issuance
      BIT
      S31820
      Societe Generale Effekten
      BIT
      I06298
      Banca Imi
      BIT
      P1NGR5
      BNP Paribas Issuance
      BIT
      1LEVI
      Levi Strauss &
      BIT
      1CVS
      CVS Health
      BIT
      MNL
      Monnalisa
      BIT
      KK
      Kruso Kapital
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads